PharmaResearch Co., Ltd. 214450

REJURAN® COSMETICS, Korea's original PDRN brand from PharmaResearch, joined LAFC's Korean Heritage Night on Wednesday, Sept. 9, as a Proud Skincare Partner of the event, bringing K-Beauty into one of Los Angeles' most dynamic sports and cultural settings.

REJURAN COSMETICS, the premium derma-cosmetic brand developed by PharmaResearch, the South Korean pharmaceutical company behind the globally recognized REJURAN® PN-based skin booster available in more than 50 countries, will launch nationwide across all 148 Sephora Canada stores on Sept. 1, marking a significant milestone in the brand's continued expansion across North America.

PharmaResearch, the biopharmaceutical company behind REJURAN®, recently participated in Aesthetics 2026, an international aesthetic medicine symposium held in Sydney, Australia. The company delivered scientific presentations and clinical education programs focused on its flagship polynucleotide (PN)-based skin booster.

PharmaResearch, the South Korea-based regenerative medicine company behind REJURAN, is strengthening its localization strategy across North America with the planned acquisition of Cosmetic Group USA, a U.S.-based cosmetics manufacturer also known as CG USA.

REJURAN COSMETICS, No.1 medical aesthetic brand developed by global pharmaceutical biotechnology company PharmaResearch, recently announced its official launch at Sephora, marking a major milestone in the brand's North American expansion. The brand is now available on sephora.com and will roll out across approximately 380 Sephora stores nationwide beginning March 16.

PharmaResearch Co., Ltd. (CEO Jihoon Sohn) announced that singer and actress Kim Sejeong has been named the new global brand ambassador for its flagship brands REJURAN® and REJURAN® COSMETICS.

PharmaResearch Co., Ltd. (CEO Jihoon Sohn), a leading regenerative medicine company, announced that it has entered into an exclusive supply agreement for Rejuran with DermaDream, a Brazilian aesthetic company, as part of its preparations for entry into the Brazilian market. The agreement was officially signed in January at IMCAS World 2026, a global aesthetic congress held in Paris, France.

PharmaResearch Co., Ltd. (CEO: Jihoon Sohn) today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PRD-101, enabling the initiation of a Phase 1 clinical trial in the United States.

As Asian markets navigate a complex landscape of regulatory changes and economic shifts, investors are increasingly focused on identifying stocks that may be priced below their intrinsic value. In this environment, a good stock is often characterized by strong fundamentals and resilience to market fluctuations, making it an attractive option for those seeking potential opportunities in undervalued equities.

As global markets navigate a period of mixed economic signals, with U.S. core consumer prices rising at their slowest pace since 2021 and value stocks outperforming growth counterparts, investors are increasingly focused on identifying undervalued opportunities. In this context, understanding what makes a stock potentially undervalued—such as strong fundamentals not yet reflected in its price—can be crucial for those looking to capitalize on estimated discounts in today's market environment.

As the Asian markets continue to show resilience amid global economic shifts, investors are increasingly seeking opportunities in undervalued stocks that could offer potential value. In this environment, identifying stocks with strong fundamentals and growth potential can be crucial for those looking to capitalize on the region's evolving economic landscape.

As the Asian markets continue to navigate a landscape marked by geopolitical tensions and economic shifts, investors are increasingly on the lookout for stocks that offer strong fundamentals at attractive valuations. Identifying undervalued stocks requires a keen eye on financial health, growth potential, and market position—factors that can provide resilience in uncertain times.

As global markets continue to navigate geopolitical tensions and economic shifts, Asian equities are capturing investor attention with their potential for growth. In this environment, identifying stocks that may be trading below their fair value can offer opportunities for investors seeking to capitalize on market inefficiencies.

As global markets kick off 2026, investors are witnessing a rally in U.S. stocks despite signs of a weakening labor market and persistent geopolitical tensions, with small-cap and value shares leading the charge. In this climate of economic uncertainty and fluctuating indices, identifying undervalued stocks becomes crucial for value investors seeking to capitalize on potential opportunities amidst these shifting dynamics.

As we step into 2026, Asian markets are showing mixed signals with Japan's stock indices experiencing slight declines and China's manufacturing sector seeing modest improvements. In this environment of fluctuating economic indicators, identifying undervalued stocks becomes crucial for investors seeking opportunities to capitalize on potential market inefficiencies.